thrombocytopenia or haemorrhage. FAIT &NAIT develops because of maternal No changes FAIT & NAIT develops because of maternal Description sensitisation to fetal platelets that possess a sensitisation to fetal platelets that possess a and paternally inherited antigen. In Caucasians, paternally inherited antigen. In Caucasians, Diagnostic the antigen is human platelet antigen (HPA) 1a the antigen is human platelet antigen (HPA) 1a Criteria in 80% of cases and HPA-5b in 15%, but other in 80% of cases and HPA-5b in 15%, but other antigens are also implicated. The mother’s antigens are also implicated. The mother’s antibodies cross the placenta and coat the antibodies cross the placenta and coat the baby’s platelets, with accelerated platelet baby’s platelets, with accelerated platelet clearance leading to thrombocytopenia. This clearance leading to thrombocytopenia. This may result in serious and potentially may result in serious and potentially bleeding in the fetus or neonate. bleeding in the fetus or neonate. Pathogenesis is analogous to that of haemolytic disease of the newborn due to red Pathogenesis is analogous to that of cell antigen–antibody incompatibility. haemolytic disease of the newborn due to red cell antigen–antibody incompatibility. The aim of management of the thrombocytopenic fetus or neonate is to increase the platelet count. The aim of management of the Instances of neonatal thrombocytopenia can thrombocytopenic fetus or neonate is to treat occur in situations where the mother has or prevent severe bleeding by increasing the idiopathic (autoimmune) thrombocytopenic platelet count. purpura (ITP). If fetal blood sampling reveals thrombocytopenia, IVIg may be administered Instances of neonatal thrombocytopenia can weekly to the mother, with or without also occur in situations where the mother has steroids, until delivery. Recent studies using
thrombocytopenia or haemorrhage. Description and Diagnostic Criteria FAIT & NAIT develops because of maternal sensitisation to fetal platelets that possess a paternally inherited antigen. In Caucasians, the antigen is human platelet antigen (HPA) 1a in 80% of cases and HPA-5b in 15%, but other antigens are also implicated. The mother’s antibodies cross the placenta and coat the baby’s platelets, with accelerated platelet clearance leading to thrombocytopenia. This may result in serious and potentially bleeding in the fetus or neonate. Pathogenesis is analogous to that of haemolytic disease of the newborn due to red cell antigen–antibody incompatibility. The aim of management of the thrombocytopenic fetus or neonate is to increase the platelet count. Instances of neonatal thrombocytopenia can occur in situations where the mother has idiopathic (autoimmune) thrombocytopenic purpura (ITP). If fetal blood sampling reveals thrombocytopenia, IVIg may be administered weekly to the mother, with or without steroids, until delivery. Recent studies using FAIT &NAIT develops because of maternal sensitisation to fetal platelets that possess a paternally inherited antigen. In Caucasians, the antigen is human platelet antigen (HPA) 1a in 80% of cases and HPA-5b in 15%, but other antigens are also implicated. The mother’s antibodies cross the placenta and coat the baby’s platelets, with accelerated platelet clearance leading to thrombocytopenia. This may result in serious and potentially bleeding in the fetus or neonate. Pathogenesis is analogous to that of haemolytic disease of the newborn due to red cell antigen–antibody incompatibility. The aim of management of the thrombocytopenic fetus or neonate is to treat or prevent severe bleeding by increasing the platelet count. Instances of neonatal thrombocytopenia can also occur in situations where the mother has No changes
Fetal-and-neonatal-alloimmune-thrombocytopenia%28FNAIT%292017.docx